ASH 2020 | Adapting myeloma treatment during the COVID-19 pandemic
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute, Charlotte, NC, shares insight into how the field of multiple myeloma treatment has adapted to the COVID-19 pandemic. Under extraordinary circumstances, healthcare systems have employed virtual methods of carrying out medical care to reduce hospital visitations. Similarly, digital platforms have been utilized to enable the continuation of innovation, education and sharing of scientific knowledge. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx and Takeda; and has received speaking fees from Celgene, Janssen, Sanofi and Takeda.
